Equities Analysts Offer Predictions for BMY FY2026 Earnings

Bristol Myers Squibb Company (NYSE:BMY) – Equities research analysts at Zacks Research raised their FY2026 earnings per share estimates for shares of Bristol Myers Squibb in a research report issued on Friday, September 11th. Zacks Research analyst Team now anticipates that the biopharmaceutical company will earn $6.86 per share for the year, up from their previous estimate of $6.85. The consensus estimate for Bristol Myers Squibb’s current full-year earnings is $6.95 per share. Zacks Research also issued estimates for Bristol Myers Squibb’s Q4 2026 earnings at $1.65 EPS, Q2 2027 earnings at $1.74 EPS, Q4 2027 earnings at $1.53 EPS, FY2027 earnings at $6.23 EPS, Q1 2028 earnings at $1.47 EPS, Q2 2028 earnings at $1.37 EPS and FY2028 earnings at $5.17 EPS.

Other research analysts have also recently issued research reports about the stock. Cantor Fitzgerald restated a “neutral” rating and issued a $59.00 target price (up from $54.00) on shares of Bristol Myers Squibb in a report on Friday, July 31st. BMO Capital Markets reiterated a “market perform” rating on shares of Bristol Myers Squibb in a research note on Monday, July 27th. Guggenheim reissued a “buy” rating and issued a $75.00 price target (up from $72.00) on shares of Bristol Myers Squibb in a research report on Friday, July 31st. Citigroup restated a “neutral” rating and issued a $70.00 price objective (up from $66.00) on shares of Bristol Myers Squibb in a research note on Monday, August 3rd. Finally, Piper Sandler initiated coverage on Bristol Myers Squibb in a report on Wednesday, August 5th. They set an “overweight” rating on the stock. One research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, ten have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $66.33.

Bristol Myers Squibb Stock Down 0.6%

BMY stock opened at $63.69 on Monday. The stock has a market cap of $130.10 billion, a P/E ratio of 14.03, a PEG ratio of 0.31 and a beta of 0.23. The company has a current ratio of 1.53, a quick ratio of 1.38 and a debt-to-equity ratio of 1.89. Bristol Myers Squibb has a twelve month low of $42.52 and a twelve month high of $68.64. The company’s 50 day moving average is $63.87 and its two-hundred day moving average is $60.10.

Bristol Myers Squibb (NYSE:BMY) last issued its earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share for the quarter, topping the consensus estimate of $1.60 by $0.44. The business had revenue of $12.97 billion for the quarter, compared to analyst estimates of $11.74 billion. Bristol Myers Squibb had a return on equity of 66.90% and a net margin of 18.87%.The business’s quarterly revenue was up 5.7% on a year-over-year basis. During the same quarter last year, the company earned $1.46 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS.

Insider Activity

In other news, SVP Phil M. Holzer sold 500 shares of Bristol Myers Squibb stock in a transaction on Tuesday, August 25th. The shares were sold at an average price of $67.50, for a total value of $33,750.00. Following the transaction, the senior vice president directly owned 16,862 shares of the company’s stock, valued at $1,138,185. The trade was a 2.88% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 0.05% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Life Cycle Investment Partners Ltd bought a new stake in Bristol Myers Squibb in the 4th quarter valued at about $34,406,000. Lazard Asset Management LLC grew its position in Bristol Myers Squibb by 23.7% in the 1st quarter. Lazard Asset Management LLC now owns 1,924,036 shares of the biopharmaceutical company’s stock worth $116,693,000 after purchasing an additional 368,193 shares during the last quarter. Axxcess Wealth Management LLC grew its position in Bristol Myers Squibb by 27.4% in the 4th quarter. Axxcess Wealth Management LLC now owns 98,665 shares of the biopharmaceutical company’s stock worth $5,322,000 after purchasing an additional 21,196 shares during the last quarter. Callan Family Office LLC acquired a new stake in shares of Bristol Myers Squibb in the second quarter valued at approximately $3,575,000. Finally, BlackRock Inc. raised its holdings in shares of Bristol Myers Squibb by 5.1% during the second quarter. BlackRock Inc. now owns 180,384,994 shares of the biopharmaceutical company’s stock valued at $10,393,783,000 after buying an additional 8,702,106 shares during the last quarter. 76.41% of the stock is owned by hedge funds and other institutional investors.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company that discovers, develops and commercializes prescription medicines. Its portfolio includes therapies for cancer, blood disorders, cardiovascular disease, immune-mediated conditions and psychiatric disorders. Key products include Opdivo and Yervoy for oncology, Eliquis for reducing the risk of stroke and systemic embolism, Revlimid for certain blood cancers, and several other specialty medicines.

The company serves patients and healthcare providers in markets around the world, with operations and commercial activities spanning North America, Europe, Asia-Pacific and other international regions.